The Mount Sinai Tisch Cancer Center has become one of the first elite research institutions in the United States to automate the transfer of clinical data from its electronic health record system into clinical trial platforms, helping doctors and researchers share information faster and more accurately during cancer clinical trials.
Powered by IgniteData’s Archer platform and integrated with Epic, the electronic medical record system used by Mount Sinai to securely document patient care, this new capability streamlines how clinical information moves between patient visits and research databases in real time.
In the past, research teams had to re-enter the same information into multiple systems, including electronic data capture (EDC) systems, specialized databases used by clinical trial sponsors to store study information for analysis and regulatory submission. This repetitive process leads to delays, transcription errors, and administrative burden. With Archer, structured data flows securely and automatically from Epic into sponsor EDC systems using HL7® FHIR® standards, a universal, health care-specific data language that ensures information moves between systems accurately, consistently, and securely.
Early pilots of the technology have shown reductions of up to 70 percent in manual transcription time, improving both data quality and workforce efficiency. The approach also allows oversight bodies to review aggregated safety and trial data sooner, helping Mount Sinai and its partners identify trends, respond to potential concerns, and accelerate decision-making during development of new therapies.
“This integration marks a turning point in how we conduct clinical trials,” said Karyn Goodman, MD, MS, Professor and Vice Chair of Clinical Research in the Department of Radiation Oncology and Associate Director of Clinical Research at Mount Sinai’s Tisch Cancer Institute. “By automating data transfer and improving accuracy at the source, we can conduct more studies, reach more patients, and deliver promising therapies faster.”
This initiative also strengthens the Mount Sinai Tisch Cancer Center’s new designation from the National Cancer Institute as a Comprehensive Cancer Center. Institutions are evaluated not only on scientific innovation but also on their ability to run complex, high-quality clinical trials and their demonstrated progress in research operations, data integrity, and multisite coordination. By deploying advanced electronic systems that ensure accurate, real-time data submission and streamlined safety reporting, Mount Sinai is demonstrating the operational maturity needed to manage large multicenter trial networks and lead in next-generation research infrastructure.
“Our research workforce is highly specialized, and their time is best spent with patients—not retyping data,” said Therica Miller, MBA, CCRP, Executive Director of Enterprise Cancer Clinical Research at Mount Sina’s Tisch Cancer Institute. “This effort improves accuracy, reduces burnout, and enhances our capacity to deliver more trials to more communities.”
The technology is currently live across Mount Sinai, beginning with oncology, with additional specialties to follow.
###
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.